Celltrion 2025 Operating Profit 1 Trillion Won: High-Margin Strategy Drives Record Growth
Celltrion expects its 2025 operating profit to exceed 1 trillion won for the first time. Explore the drivers behind this record growth and its US market strategy.
South Korean biopharmaceutical giant Celltrion Inc. is poised to join the elite '1 trillion won club' for the first time in its history. According to a company announcement on December 31, 2025, strong sales of high-end biosimilars are expected to more than double the company's profitability in the coming year.
Celltrion 2025 Operating Profit 1 Trillion Won: Breaking Milestones
Celltrion's forecast for 2025 is ambitious, with an operating profit target of 1.16 trillion won ($804 million). This represents a massive jump from the 492 billion won recorded in 2024. Total sales are also projected to reach 4.11 trillion won, driven by the global expansion of flagship products such as Remsima SC, Yuflyma, and Vegzelma.
| Metric | 2024 (Est.) | 2025 (Forecast) |
|---|---|---|
| Revenue | 3.56 trillion won | 4.11 trillion won |
| Operating Profit | 492 billion won | 1.16 trillion won |
Strategic Shifts: Eli Lilly Partnership and US Direct Sales
The company doesn't just plan to sell more; it's optimizing how it makes and delivers medicine. Celltrion USA is set to finalize the 460 billion won acquisition of a production plant in New Jersey from Eli Lilly. This facility will support both Contract Manufacturing Organization (CMO) services for Eli Lilly and the roll-out of Celltrion’s own products in the lucrative US market. With the number of approved products rising from six to 11, the firm aims to have 18 commercialized biosimilars by 2030.
Investors should note that profitability depends heavily on the successful transition to direct sales in the US and navigating the competitive landscape of the PBM (Pharmacy Benefit Manager) lists.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Novo Nordisk slashes Wegovy prices in China to fight off competition from Eli Lilly and local firms. Discover the impact on the $20B Chinese obesity market.
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.
The S&P 500 and Nasdaq ended 2025 slightly lower in thin trading. Meta gained on a new deal, highlighting a quiet finale for the U.S. markets on Dec 31, 2025.
Novo Nordisk slashes Wegovy prices in China to fight off competition from Eli Lilly and local firms. Discover the impact on the $20B Chinese obesity market.
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.
The S&P 500 and Nasdaq ended 2025 slightly lower in thin trading. Meta gained on a new deal, highlighting a quiet finale for the U.S. markets on Dec 31, 2025.